About BioRay Pharmaceutical
BioRay Pharmaceutical is a company based in Taizhou (China) founded in 2019 was acquired by PAG in September 2019. BioRay Pharmaceutical has raised $214.97 million across 1 funding round from investors including PAG. BioRay Pharmaceutical operates in a competitive market with competitors including Moderna, BeiGene, Incyte, Horizon Therapeutics and Forge Biologics, among others.
- Headquarter Taizhou, China
- Stage Unicorn
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Bioray Pharmaceutical Corp
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of BioRay Pharmaceutical
Unlock access to complete
Unlock access to complete
Funding Insights of BioRay Pharmaceutical
BioRay Pharmaceutical has successfully raised a total of $214.97M through 1 strategic funding round. The most recent funding activity was a Series D round of $214.97 million completed in December 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in BioRay Pharmaceutical
BioRay Pharmaceutical has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include PAG.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Alternative investment firm
|
Locked | Locked | Locked |
Investor details for BioRay Pharmaceutical
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by BioRay Pharmaceutical
Investment portfolio details for BioRay Pharmaceutical
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - BioRay Pharmaceutical
Detailed financials for BioRay Pharmaceutical
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Bioray Pharmaceutical Comparisons
Peer comparison for BioRay Pharmaceutical
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of BioRay Pharmaceutical
BioRay Pharmaceutical operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BeiGene, Incyte, Horizon Therapeutics and Forge Biologics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Developer of drugs for treating rare and autoimmune diseases
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases are developed to treat patients.
|
|
| Locked | Locked | Locked |
Therapeutic antibodies for cancer and other diseases are developed.
|
Detailed competitors of BioRay Pharmaceutical
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Bioray Pharmaceutical
Complete news archive for BioRay Pharmaceutical
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BioRay Pharmaceutical
BioRay Pharmaceutical was founded in 2019 and raised its 1st funding round 3 years after it was founded.
BioRay Pharmaceutical is headquartered in Taizhou, China. It is registered at Taizhou, Jiangsu, China.
Haibin Wang is the current CEO of BioRay Pharmaceutical.
BioRay Pharmaceutical is a funded company, having raised a total of $214.97M across 1 funding round to date.
BioRay Pharmaceutical was founded in 2019 in Taizhou, China, within the biotechnology sector. Therapeutics are developed using an antibody-technology platform targeted at immune-mediated diseases, including rheumatoid arthritis, psoriasis, and Ankylosing Spondylitis. Drugs for cancer and tumors are also offered. Formulated products derived from organic ingredients are provided to support health restoration and bodily balance. Operations focus on immunology and oncology research and development.
BioRay Pharmaceutical has 1 investor. Key investors include PAG.
The valuation of BioRay Pharmaceutical is $1.9B as of Dec 2022.